Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Author Name Lorena Incorvaia et al Category Computer science, information & general works Type Journal Tags Checkpoint inhibitors,lung cancer,NSCLC,PD-1,PD-L1,Pembrolizumab,Predictive biomarker Login to Access Content
